Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:LTYNASDAQ:MDNANASDAQ:ONCNASDAQ:PDP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLTYLiberty BiopharmaC$2.00+∞C$2.00C$0.06▼C$2.74C$21.54MN/A23,286 shs700 shsMDNAMedicenna Therapeutics$0.29$0.15▼$0.84$10.93M1.3160,047 shs1.27 million shsONCBeOne Medicines$252.78-0.5%$245.25$141.31▼$287.88$27.69B0.3309,136 shs230,441 shsPDPInvesco Dorsey Wright Momentum ETF$104.60-0.3%$102.53$86.41▼$117.67$1.23B1.1321,507 shs15,663 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLTYLiberty Biopharma0.00%0.00%0.00%0.00%0.00%MDNAMedicenna Therapeutics0.00%0.00%0.00%0.00%0.00%ONCBeOne Medicines0.00%-8.59%+6.72%+0.32%+25,277,999,900.00%PDPInvesco Dorsey Wright Momentum ETF0.00%-1.41%-1.53%+2.92%+4.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLTYLiberty BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONCBeOne Medicines2.4476 of 5 stars3.50.00.00.02.81.70.6PDPInvesco Dorsey Wright Momentum ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLTYLiberty Biopharma 0.00N/AN/AN/AMDNAMedicenna Therapeutics 3.00Buy$2.50∞ UpsideONCBeOne Medicines 3.00Buy$319.0026.20% UpsidePDPInvesco Dorsey Wright Momentum ETF 2.68Moderate Buy$104.60N/ACurrent Analyst Ratings BreakdownLatest LTY, ONC, MDNA, and PDP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.005/8/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$348.00 ➝ $350.004/28/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$312.00 ➝ $312.004/24/2025ONCBeOne MedicinesTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$334.00 ➝ $334.004/21/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$311.00 ➝ $317.004/16/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/10/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$348.00 ➝ $348.004/7/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$312.004/7/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy$312.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLTYLiberty BiopharmaN/AN/AC$0.00 per share2,000.00C$0.79 per shareN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/A$0.32 per shareN/AONCBeOne Medicines$3.81B7.27N/AN/A$34.10 per share7.41PDPInvesco Dorsey Wright Momentum ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLTYLiberty BiopharmaN/A-C$0.16N/A∞N/AN/AN/AN/AN/AMDNAMedicenna Therapeutics-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/AONCBeOne Medicines-$644.79M-$3.72N/A356.03N/A-9.40%-7.55%-4.42%N/APDPInvesco Dorsey Wright Momentum ETFN/AN/A27.88∞N/AN/AN/AN/AN/ALatest LTY, ONC, MDNA, and PDP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ONCBeOne Medicines-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLTYLiberty BiopharmaN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/APDPInvesco Dorsey Wright Momentum ETF$0.180.17%N/AN/AN/ALatest LTY, ONC, MDNA, and PDP DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/24/2025PDPInvesco Dorsey Wright Momentum ETF$0.04583/24/20253/24/20253/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLTYLiberty Biopharma8.190.120.12MDNAMedicenna TherapeuticsN/A9.579.57ONCBeOne Medicines0.051.961.71PDPInvesco Dorsey Wright Momentum ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLTYLiberty BiopharmaN/AMDNAMedicenna Therapeutics12.38%ONCBeOne Medicines48.55%PDPInvesco Dorsey Wright Momentum ETFN/AInsider OwnershipCompanyInsider OwnershipLTYLiberty BiopharmaN/AMDNAMedicenna Therapeutics33.10%ONCBeOne Medicines6.62%PDPInvesco Dorsey Wright Momentum ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLTYLiberty BiopharmaN/A10.77 millionN/ANot OptionableMDNAMedicenna Therapeutics1669.64 million46.59 millionNot OptionableONCBeOne Medicines11,000109.56 million102.31 millionN/APDPInvesco Dorsey Wright Momentum ETFN/A11.73 millionN/AOptionableLTY, ONC, MDNA, and PDP HeadlinesRecent News About These CompaniesHigh-Beta & Momentum ETFs to Play on Hints of Easing Trade Tensions?April 23, 2025 | zacks.comETFs For The Brave: Are These High-Octane Funds Your Best Bet To Ride An Upward Market Swing?April 15, 2025 | benzinga.comBuy High Beta & High Momentum ETFs for Near-Term GainsApril 10, 2025 | zacks.comBuy High Beta & High Momentum ETFs for Near-Term GainsApril 10, 2025 | zacks.comInvesco Exchange-Traded Fund Trust Invesco Dorsey Wright Momentum ETFMarch 25, 2025 | fxempire.comPIZ Invesco Dorsey Wright Developed Markets Momentum ETFNovember 22, 2024 | seekingalpha.comPDP, TRGP, WRB, TDG: Large Inflows Detected at ETFOctober 3, 2024 | nasdaq.com(PDP) Investment AnalysisSeptember 17, 2024 | news.stocktradersdaily.comPDP Invesco Dorsey Wright Momentum ETFAugust 28, 2024 | seekingalpha.comTime for Momentum ETFs?August 20, 2024 | zacks.comMomentum ETFs to Play as Wall Street Rallies?August 16, 2024 | zacks.comInvesco Dorsey Wright Momentum ETF (PDP)November 28, 2023 | finance.yahoo.comInvesco DWA Developed Markets Momentum ETF (PIZ)August 18, 2023 | investing.comInvesco DWA Emerging Markets Momentum ETFJune 30, 2023 | thestreet.comIs Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) a Strong ETF Right Now?February 24, 2023 | msn.comGTO Invesco Actively Managed Exchange-Traded Fund Trust - Invesco Total Return Bond ETFFebruary 23, 2023 | seekingalpha.comInvesco DWA Consumer Cyclicals Momentum ETF (PEZ)December 25, 2022 | finance.yahoo.comPEZ Invesco Exchange-Traded Fund Trust - Invesco DWA Consumer Cyclicals Momentum ETFOctober 11, 2022 | seekingalpha.comInvesco DWA Momentum ETF declares quarterly distribution of $0.0830September 22, 2022 | seekingalpha.comInvesco DWA Momentum ETF declares quarterly distribution of $0.0237June 21, 2022 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsBy Leo Miller | May 27, 2025View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsTurbulence for Joby Shares: What's Behind the Recent Dip?By Jeffrey Neal Johnson | May 22, 2025View Turbulence for Joby Shares: What's Behind the Recent Dip?RKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernCostco Stock at $1K: Dominance or Danger Zone?By Jeffrey Neal Johnson | May 23, 2025View Costco Stock at $1K: Dominance or Danger Zone?LTY, ONC, MDNA, and PDP Company DescriptionsLiberty Biopharma CVE:LTYC$2.00 +2.00 (+∞) As of 10/10/2018Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.Medicenna Therapeutics NASDAQ:MDNAMedicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.BeOne Medicines NASDAQ:ONC$252.78 -1.31 (-0.52%) As of 06/18/2025 04:00 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Invesco Dorsey Wright Momentum ETF NASDAQ:PDP$104.60 -0.34 (-0.32%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$104.60 +0.01 (+0.00%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PowerShares DWA Technical Leaders Portfolio (the Fund) is based on the Dorsey Wright Technical Leaders Index (the Index). The Fund seeks investment results that generally correspond to the price and yield of the Index. The Fund will normally invest at least 90% of its total assets in securities that consists of the Index and American Depositary Receipts (ADRs) based on the securities in the Index. The Index includes approximately 100 the United States-listed companies. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
